Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case-malformed signal detection and prioritisation using EUROmediCAT data for pharmacovigilance in pregnancy.

British journal of clinical pharmacology·2026
Same author

The PIECES multi-site comparative case study protocol: mixed methods implementation evaluation of adapting, implementing and tailoring primary cancer prevention programmes in diverse contexts.

Implementation science communications·2026
Same author

Diabetes and Cancer-Specific Survival: A Nationwide Population-Based Cohort Study Across Multiple Cancer Sites.

Cancer reports (Hoboken, N.J.)·2026
Same author

Gabapentin and Pregabalin Use in First Trimester of Pregnancy and Risk of Specific Congenital Anomalies: An IMI ConcePTION European Case-Malformed Control Study.

Drug safety·2026
Same author

From Soil to Serum: Matrix-Specific Per- and Polyfluoroalkyl Substance Accumulation and Potentially Associated Environmental Exposure Determinants in Teenagers Residing near an Industrial Hotspot.

Toxics·2026
Same author

Efficacy of Levetiracetam in Patients With Pediatric Epilepsy: A Systematic Review and Meta-Analysis.

Neurology·2026

Related Experiment Video

Updated: Jul 5, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Cancer detection in the European Randomised Study of Screening for Prostate Cancer (ERSPC).

Niko Pasanen1,2, Kirsi Talala3, Sebastiaan Remmers4

  • 1Faculty of Social Sciences, Tampere University, Tampere, Finland.

BJU International
|July 4, 2026
PubMed
Summary

Repeated prostate cancer screening shows declining low-grade detection and varied high-grade detection across centers. This suggests personalized screening and better participation strategies are needed.

Keywords:
mortalityoverdiagnosisprostate cancerrandomised trialsscreening

More Related Videos

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
08:05

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

Related Experiment Videos

Last Updated: Jul 5, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
08:05

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

Area of Science:

  • Urology
  • Oncology
  • Public Health

Background:

  • The European Randomised Study of Screening for Prostate Cancer (ERSPC) aimed to evaluate prostate cancer screening effectiveness.
  • Understanding outcomes of repeated screening and detection rates for different cancer grades is crucial.

Purpose of the Study:

  • To analyze outcomes of repeated screening in the ERSPC, focusing on detection rates of low-grade versus high-grade prostate cancer.
  • To assess variations in cancer detection rates across different European centers and screening cycles.

Main Methods:

  • Analysis of men aged 55-69 years across ERSPC trial centers (excluding France).
  • Classification of men into ever-attenders and non-attenders within the screening arm.
  • Calculation of cancer detection rates (CDRs) by age group and center over three screening cycles, including interval cancers.

Main Results:

  • Cancer detection rates were consistently higher for low-grade than for intermediate- and high-grade prostate cancer.
  • Trends in high-grade cancer detection rates varied significantly by center, with some showing decreases then increases, while others demonstrated consistent increases.
  • Increasing rates of interval and non-attender cancers were observed.

Conclusions:

  • Repeated screening in ERSPC shows a decreasing detection rate for low-grade prostate cancer.
  • Significant inter-center variation exists in detecting intermediate- and high-grade prostate cancer.
  • Findings support a shift towards personalized screening schedules and strategies to enhance participant engagement.